XML 41 R22.htm IDEA: XBRL DOCUMENT
v3.25.1

ADDITIONAL FINANCIAL STATEMENT INFORMATION | 12 Months Ended
--- | ---
Dec. 31, 2024
ADDITIONAL FINANCIAL STATEMENT INFORMATION |
ADDITIONAL FINANCIAL STATEMENT INFORMATION | 16. ADDITIONAL FINANCIAL STATEMENT INFORMATION Certain balance sheet amounts are comprised of the following (in thousands) for the periods presents:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31, 2024 |  | December 31, 2023
Accounts receivable, net: | ​ | ​ | ​ | ​ | ​ | ​
Oil, natural gas and natural gas liquids revenues | ​ | $ | 23,516 | ​ | $ | 19,802
Joint interest accounts | ​ | ​ | 2,140 | ​ | ​ | 2,138
Other | ​ | ​ | 642 | ​ | ​ | 1,081
​ | ​ | $ | 26,298 | ​ | $ | 23,021
Prepaids and other: | ​ | ​ | ​ | ​ | ​ | ​
Prepaids | ​ | $ | 572 | ​ | $ | 490
Funds in escrow | ​ | ​ | 349 | ​ | ​ | 345
Other | ​ | ​ | 61 | ​ | ​ | 72
​ | ​ | $ | 982 | ​ | $ | 907
Other assets (Non-current): | ​ | ​ | ​ | ​ | ​ | ​
Investment in unconsolidated affiliate | ​ | $ | 940 | ​ | $ | 1,283
Contract asset | ​ | ​ | — | ​ | ​ | 15,062
Funds in escrow | ​ | ​ | 578 | ​ | ​ | 552
Other | ​ | ​ | 760 | ​ | ​ | 759
​ | ​ | $ | 2,278 | ​ | $ | 17,656
Accounts payable and accrued liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Trade payables | ​ | $ | 15,663 | ​ | $ | 24,915
Accrued oil and natural gas capital costs | ​ | ​ | 7,800 | ​ | ​ | 15,337
Revenues and royalties payable | ​ | ​ | 19,816 | ​ | ​ | 18,986
Accrued interest expense | ​ | ​ | 330 | ​ | ​ | 347
Accrued employee compensation | ​ | ​ | 1,472 | ​ | ​ | 520
Accrued lease operating expenses | ​ | ​ | 7,597 | ​ | ​ | 6,418
Other | ​ | ​ | 4 | ​ | ​ | 2
​ | ​ | $ | 52,682 | ​ | $ | 66,525
​ Investment in Unconsolidated Affiliate. In May 2022, the Company entered into a joint venture with Caracara Services, LLC (“Caracara”) to develop an acid gas treatment facility to remove hydrogen sulfide and carbon dioxide from its produced natural gas. Caracara provided the initial capital for the construction of the treatment facility. The Company contributed certain full cost pool assets to the related party joint venture in a non-cash exchange for a retained 5% equity interest in Wink Amine Treater, LLC (“WAT”) (previously Brazos Amine Treater, LLC (“BAT”)), an unconsolidated subsidiary. For accounting purposes, since the Company does not control the key activities (e.g. operating and maintaining the facility) which most significantly impact economic performance, the Company is not the primary beneficiary of WAT. Accordingly, the Company accounts for its investment in WAT (a related party) using the equity method of accounting based on its ability to exercise significant influence, but not control, over the key activities of the joint venture. For more information related to this joint venture, see Note 11, “Commitments and Contingencies”. Contract Asset. The Company has advanced total capital contributions of approximately $18.5 million on behalf of its joint venture partner in WAT to fund a workover operation on the AGI Facility. Pursuant to the terms of the agreement governing the joint venture, the Company has multiple remedies to recover such advance, including (1) declaring such payment a loan, which pursuant to the agreement would have an interest rate of the lesser of 15% or the maximum rate permitted by law, (2) recoupment from distributions from the joint venture and (3) reallocation of equity of the joint venture based on the relative level of total capital contributions by the parties after taking into account the advances, none of which would occur until the expiration of the current tolling agreement between the parties. The Company assesses the fair value of the contract asset on a quarterly basis for possible impairment. During the fourth quarter of 2024, the Company identified indicators that the carrying value of the contract asset may not be recoverable and as a result, recognized $18.5 million of impairment of charges to reduce the carrying value of the contract asset to zero at December 31, 2024. ​ Certain income statement amounts are comprised of the following (in thousands) for the periods presents:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31, 2024 |  | December 31, 2023
Interest expense and other | ​ | ​ | ​ | ​ | ​ | ​
Interest expense | ​ | $ | 29,009 | ​ | $ | 36,511
Interest income | ​ | ​ | (2,122) | ​ | ​ | (1,243)
Mark-to-market of derivatives - change of control call option | ​ | ​ | (2,084) | ​ | ​ | (2,053)
Merger Termination Payment | ​ | ​ | (10,000) | ​ | ​ | —
Other | ​ | ​ | 153 | ​ | ​ | 104
​ | ​ | $ | 14,956 | ​ | $ | 33,319
​

X
- References No definition available. + Details
Name: | batl_AdditionalFinancialInformationDisclosureAbstract
Namespace Prefix: | batl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration